IB3/IIA2 stage cervical cancer
Conditions
Interventions
Treatment group:QL1706 Combined Standard Chemotherapy Regimen
Sponsors
The First Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Pathologically confirmed as cervical cancer (squamous carcinoma, adenocarcinoma, or adenosquamous carcinoma), and according to the FIGO 2018 clinical staging, it is stage IB3 and IIA2 (tumor maximum diameter >4 cm). 2.Aged between 18 and 75 years old; 3.The patient's physical condition can tolerate chemotherapy and surgical treatment. 4.ECOG score 0-1. 5.Expected survival period exceeds 6 months; 6.The patient voluntarily joined the study and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Previously received chemotherapy, radiotherapy, or surgical treatment for cervical cancer, as well as immunotherapy or targeted therapy. 2.There are serious comorbidities, such as severe cardiovascular and cerebrovascular diseases, liver and kidney failure, etc.; 3.Combine with other malignant tumors; 4.Those with a history of drug allergies or severe adverse reactions; 5.Pregnant or breastfeeding women. 6.At the same time, undergo other treatments targeting the tumor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathological complete response (pCR); | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate (ORR);Progression-Free Survival (PFS);Incidence of adverse events; | — |
Countries
China
Contacts
Public ContactChunhua Tu
The First Affiliated Hospital of Nanchang University
Outcome results
None listed